Protocols: The Mylan furor comes into play for California drug initiative; Adocia concedes a PhIII flop
There were times this week where it would have been hard to believe that something other than the EpiPen scandal was going on in the industry. These furors suck up oxygen like a forest fire. And they are infinitely adaptable. In California, a LA Times columnist used the issue to highlight the $100 million pharma representatives are spending to defeat the Drug Price Relief Act, which would require some long-absent price transparency. And it would cap prices for drugs used by Medi-Cal at the (negotiated) rate paid by the VA. The alternative, says the columnist, is a system in which the Mylans of the world will continue to dominate. You can bet industry lobbyists are praying that the Mylan storm blows over soon.
Shares of France’s Adocia (PARIS: ADOC) slipped Friday morning after the company said its diabetic foot ulcer treatment BioChaperone PDGF (BC PDGF) failed a Phase III study. There was no significant improvement over a placebo in spurring wound closure after 20 weeks. “We are surprised and disappointed by these topline results, which are inconsistent with previously reported positive Phase 1/2 clinical results. Therefore, we have initiated a thorough review of the study to analyse the discrepancy in the data” said Gérard Soula, CEO of Adocia.